A substituted cathinone is a synthetic psychoactive compound built on the cathinone scaffold — a β-keto phenethylamine — carrying at least one additional modification of the aromatic ring, the nitrogen, or the alpha-carbon.[1] The class is defined by chemical structure, not by a single pharmacology: the unifying feature is the β-keto group on the phenethylamine side chain, the same single difference that separates cathinone from amphetamine.[2]
Members span a chemically broad set built outward from the natural alkaloid of *Catha edulis* (khat). The brief includes early entactogen-type compounds such as methylone, ethylone, butylone, ephylone, and eutylone; mephedrone-family stimulants such as mephedrone, 3-MMC, 2-MMC, and 3-CMC; pyrrolidine-containing analogs such as MDPV, α-PVP, and α-PHP; and structural outliers such as mexedrone and βk-2C-B. All converge on monoamine-transporter activity despite differing widely in chemistry.[3]
In practice these compounds are short-acting CNS stimulants. At lower exposure they produce alertness, mood elevation, and — in serotonin-active members — empathogenic warmth resembling MDMA; at higher exposure they produce intense euphoria, sympathomimetic load, and, in catecholamine-dominant members, marked compulsion to redose.
They are used almost entirely in recreational contexts, frequently encountered under generic market names such as "bath salts," and have repeatedly appeared as novel-psychoactive-substance replacements as older members are scheduled.[4]
Pharmacology
Every substituted cathinone acts at the plasma-membrane monoamine transporters — the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT) — and elevates synaptic dopamine, norepinephrine, and/or serotonin.[5] That shared endpoint is reached through chemically distinct routes, and the route a member takes shapes its experiential and risk profile.
| Mechanism | Representative members | How it reaches the shared endpoint |
|---|---|---|
| Non-selective transporter substrate (releaser at DAT, NET, and SERT) | methylone, ethylone, butylone, eutylone, ephylone, mephedrone | Transported into the presynaptic terminal and triggers non-exocytotic efflux of all three monoamines; a relatively high serotonin-to-dopamine release ratio produces the empathogenic, MDMA-like character[6] |
| Catecholamine-selective releaser/blocker (DAT and NET, lower SERT) | methcathinone, 3-MMC, 2-MMC, 3-CMC, hexedrone, N-ethylhexedrone, NEP, pentedrone, clephedrone | Elevates dopamine and norepinephrine without strong serotonergic enhancement, yielding a methamphetamine- or cocaine-like stimulant profile[7] |
| Pyrrolidine-ring catecholamine reuptake inhibitor (DAT, NET; negligible SERT) | MDPV, α-PVP, α-PHP, α-PiHP, ETH-CAT | Pure cocaine-like blockade of catecholamine reuptake without releasing activity; the absence of serotonergic counter-balance is associated with an intensely compulsive stimulant profile[8] |
| β-keto atypicals | mexedrone, βk-2C-B | Mexedrone's methoxy substitution substantially weakens transporter activity; βk-2C-B adds 5-HT2A agonism, shifting toward a classical-psychedelic dimension at the edge of the class[2] |
Structural details organise this variation in regular ways. The β-keto group itself raises polarity relative to amphetamine, modestly reducing blood-brain barrier penetration and shortening the duration of action across the class. N-methylation increases potency; pyrrolidine substitution at the nitrogen sharply increases DAT/NET selectivity and abolishes releasing activity; longer alkyl chains at the alpha-carbon (propyl → butyl → pentyl) extend duration; ring halogenation tends to shift selectivity from SERT toward DAT.[2]
The route to the endpoint matters less for safety than the endpoint itself: sympathomimetic catecholamine excess — driving tachycardia, hypertension, hyperthermia, and acute neuropsychiatric toxicity — is shared across the class and is additive with other stimulants.[9]
Substances
The class is illustrated by members spanning three pharmacological subgroups plus a pair of structural outliers. The roster below is representative, not exhaustive; the full member list renders separately.
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| Methylone | Entactogen-type | The first substituted cathinone reported to European monitoring bodies; the methylenedioxy analog of methcathinone, with an MDMA-like releaser profile |
| Mephedrone (4-MMC) | Entactogen-type / hybrid | Dominated European recreational markets from roughly 2008 to scheduling; a potent non-selective releaser sitting between MDMA and methamphetamine in profile |
| Eutylone | Entactogen-type | Among the more recent entactogen-type analogs to appear as a market replacement for older members |
| Methcathinone | Stimulant-type | One of the oldest synthetic analogs; structurally the closest to the natural khat alkaloid |
| 3-MMC | Stimulant-type | Rose to prominence as a meta-substituted replacement for mephedrone after scheduling; higher DAT/SERT ratio than its para-substituted cousin |
| MDPV | Pyrrolidine-type | Prototypical pyrovalerone-class member; the central agent of the early-2010s US "bath salts" wave |
| α-PVP | Pyrrolidine-type | Marketed as "flakka"; rose to prominence as a market replacement after MDPV scheduling, with similarly compulsive reinforcement |
| Mexedrone | β-keto atypical | Methoxy modification of mephedrone substantially weakens transporter activity; sits at the edge of the class |
| βk-2C-B | β-keto atypical | The β-keto homologue of 2C-B; introduces 5-HT2A agonism to the scaffold and the only member whose experiential profile crosses into the classical-psychedelic range |
These members differ widely in subjective character — from MDMA-like warmth (methylone, eutylone) to focused stimulant push (3-MMC, methcathinone) to compulsive cocaine-like drive (MDPV, α-PVP) — but each shares the β-keto phenethylamine scaffold, the same monoamine-transporter endpoint, and the class-wide sympathomimetic risk profile that follows from it.[3]
Subjective Effects
The class-wide effect trajectory is a stimulant arc, varied in colour by a member's DAT/SERT ratio. Members with more serotonin activity bring empathogenic warmth alongside the stimulation; members with negligible SERT activity produce a colder, more focused, and more compulsive push.
| Exposure | Characteristic effects |
|---|---|
| Low | Onset of arousal, alertness, reduced fatigue, mood elevation, increased sociability, appetite suppression; entactogen-type members add emotional warmth and mild sensory enhancement, while pyrrolidine-type members tend toward cold, focused stimulation |
| Moderate–high | Heightened euphoria, racing thoughts, talkativeness, hypersexuality (most prominent with pyrrolidine-type members), bruxism, insomnia, rising anxiety and agitation, dysphoria, marked cardiovascular load |
| High | Severe agitation, acute psychosis with paranoia and hallucinations, hyperthermia, cardiovascular instability, rhabdomyolysis; entactogen-type members can additionally produce hyponatremia in an MDMA-like pattern |
The β-keto group's polarity tends to produce a faster-onset, shorter-duration arc than the comparable amphetamine analogs, and that short duration is itself a feature of the class: it drives the redosing and binge patterns documented across members.[1]
The same axes that produce the sought effects — catecholamine drive for stimulation, serotonin release for empathogenic warmth — are the axes that produce the dangerous ones, and the margin between them narrows sharply as exposure rises.[10]
Safety
Risk profile
The defining acute danger of this class is sympathomimetic catecholamine excess — severe tachycardia, hypertension, cardiac arrhythmia, and hyperthermia — capable of producing cardiovascular collapse, multi-organ failure, and death. Acute psychosis with paranoia, hallucinations, and severe agitation is documented across members and is most prolonged and intense with the pyrrolidine-type compounds.US poison-centre call volumes tracking the early-2010s bath-salts crisis rose from 304 calls in 2010 to 6,136 in 2011, and US emergency-department surveillance recorded approximately 22,900 ED visits associated with cathinone use in 2011 alone.[11]
Hyperthermia is a leading acute cause of fatality across the class, and in entactogen-type members it is compounded by serotonin-toxicity risk — particularly when combined with MDMA, other serotonergic stimulants, or MAOIs.[10] Pyrrolidine-type members carry the most pronounced cardiovascular and psychiatric toxicity profile, reflecting their pure catecholamine drive without serotonergic dampening.[8]
Combination patterns matter independently of any single member's profile. Mixing any substituted cathinone with another stimulant multiplies cardiovascular load. Mixing with CNS depressants such as alcohol or benzodiazepines is particularly hazardous: stimulant effects mask the early warning signs of depressant overdose, raising the risk of respiratory depression and cardiovascular collapse as the stimulant wears off first.[9] Insufflation accelerates onset and intensifies peak effects, and injection — disproportionately associated with the pyrrolidine-type members and chemsex settings — amplifies every acute risk while introducing infectious-disease harms.[12]
A class-level risk that compounds all of the above is under-characterisation. A 2023 forensic review documented more than fifty novel cathinone analogs reported to monitoring bodies between 2019 and 2022, many with sparse toxicological data; users may assume a new analog behaves like a familiar precursor when even small structural changes can substantially alter potency and duration.[13]
Tolerance & dependence
Tolerance develops with repeated use across the class, in the general pattern of monoamine-active stimulants: escalating doses are needed to reach prior effects, and cross-tolerance is expected between members of the same pharmacological subgroup.[4] The class carries substantial dependence and abuse liability.
Preclinical self-administration places MDPV and α-PVP at or above methamphetamine in reinforcing efficacy,[9] and pre-scheduling surveys of mephedrone users found roughly 30% meeting DSM-IV criteria for dependence.[4] Pyrrolidine-type members carry the highest compulsive-use potential — sustained binges across many hours or days are prominently documented for MDPV and α-PVP.[8]
Withdrawal from heavy use is a stimulant-type syndrome: intense craving, profound dysphoria, fatigue, hypersomnia, depression, anhedonia, and impaired concentration. Unlike alcohol or benzodiazepine withdrawal, it does not carry a medically dangerous seizure risk in most cases.
The psychological intensity is the leading clinical concern — particularly the dysphoria and suicidality risk during the comedown from heavy pyrrolidine-type binges, and the possibility that stimulant-induced psychosis outlasts the withdrawal phase and requires separate psychiatric management.[10]
Recovery
Dependence on substituted cathinones is treatable. No class-specific medical withdrawal protocol is established; clinical management follows general stimulant-withdrawal practice — supportive care, sleep and mood symptom management, monitoring for persistent psychiatric symptoms, and longer-term psychosocial support to address relapse risk during the dysphoric comedown.If you or someone you know is using heavily, has experienced acute psychosis, or is struggling to stop, a clinician, addiction service, or harm-reduction service can structure ongoing care. Stimulant-induced psychotic symptoms that persist beyond the acute period warrant separate psychiatric assessment.[10]
Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1] ^abKuropka, P. and Zawadzki, M. and Szpot, P. (2023) A narrative review of the neuropharmacology of synthetic cathinones — Popular alternatives to classical drugs of abuse — Human Psychopharmacology: Clinical and Experimental doi:10.1002/hup.2866
- [2] ^abcdNadal-Gratacós N, Pazos MD, Pubill D, Camarasa J, Escubedo E, Berzosa X, López-Arnau R (2024) Structure-Activity Relationship of Synthetic Cathinones: An Updated Review — ACS Pharmacology and Translational Science doi:10.1021/acsptsci.4c00299
- [3] ^abSoares, J. and Costa, V.M. and Bastos, M.L. and Carvalho, F. and Capela, J.P. (2021) An updated review on synthetic cathinones — Archives of Toxicology doi:10.1007/s00204-021-03083-3
- [4] ^abcKarila, L. and Megarbane, B. and Cottencin, O. and Lejoyeux, M. (2015) Synthetic cathinones: a new public health problem — Current Neuropharmacology doi:10.2174/1570159x13666141210224137
- [5] ^Baumann, M.H. and Partilla, J.S. and Lehner, K.R. (2013) Psychoactive 'bath salts': not so soothing — European Journal of Pharmacology doi:10.1016/j.ejphar.2012.11.020
- [6] ^Cameron, K. and Kolanos, R. and Vekariya, R. and De Felice, L. and Glennon, R.A. (2013) Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of 'bath salts,' produce opposite effects at the human dopamine transporter — Psychopharmacology doi:10.1007/s00213-013-2967-2